PERCHERON THERAPEUTICS LIMITED — Director's Dealing 2021

Dec 21, 2021

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Antisense Therapeutics Limited (ASX: ANP)
ABN 41 095 060 745

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mark Diamond
Date of last notice	03 December 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	-
Date of change	22 December 2021
No. of securities held prior to change		Shares	Options
	Direct	4,423,173	14,000,000
	Indirect	-	-
	Total	4,423,173	14,000,000
Class	a)Fully Paid Ordinary Sharesb)Unlisted Options
Number acquired		Shares	Options
	Direct	470,549	235,274
	Indirect	-	-
	Total	470,549	235,274
Number disposed
		Shares-	Options-
	DirectIndirect	-	-

Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	$112,931.76
No. of securities held after change
		Shares	Options
	Direct	4,893,722	14,235,274
	Indirect	-	-
	Total	4,893,722	14,235,274
Nature of change	a & b) Issue of sharesand free-attaching
Example: on-market trade, off-market trade, exercise of options,issue of securities under dividend reinvestment plan, participationin buy-back	optionsas per Entitlement Offer

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide detailsand an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed	No
above traded during a +closed periodwhere prior writtenclearance was required?
If so, was prior written clearance provided to allow thetrade to proceed during this period?	N/A
If prior written clearance was provided, on what date wasthis provided?	N/A

22 December 2021